secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001104659-24-119701
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata extends debt maturity to Jan 2026, terminates CMO, hires senior finance and regulatory leaders
--------------------------------------------------------------------------------

- Amended credit agreements with Innoviva; maturity moved to January 10, 2026.
- Terminated Chief Medical Officer Mina Pastagia, M.D., effective Nov 13, 2024; eligible for 12 months base salary severance.
- Hired David House as SVP Finance and Principal Financial Officer; hired Arwa Shurrab to lead regulatory strategy and operations.
- Preparing for two potential Phase 3 licensure-supporting trials in 2025 with expanded clinical and regulatory team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/0001104659-24-119701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/tm2428608d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer